Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
55 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Measles - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Measles - Pipeline Review, H2 2014', provides an overview of the Measles's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Measles and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Measles - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Measles and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Measles products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Measles pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Measles - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Measles pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Measles Overview 7 Therapeutics Development 8 Pipeline Products for Measles - Overview 8 Pipeline Products for Measles - Comparative Analysis 9 Measles - Therapeutics under Development by Companies 10 Measles - Therapeutics under Investigation by Universities/Institutes 12 Measles - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Measles - Products under Development by Companies 16 Measles - Products under Investigation by Universities/Institutes 17 Measles - Companies Involved in Therapeutics Development 18 Vical Incorporated 18 GlaxoSmithKline plc 19 Zydus Cadila Healthcare Limited 20 Cadila Pharmaceuticals Ltd. 21 Beijing Tiantan Biological Products Co., Ltd. 22 Serum Institute of India Limited 23 Universal Stabilization Technologies, Inc. 24 Measles - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 measles, mumps and rubella vaccine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 M-Vac - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Vaccine for Live Measles, Mumps and Rubella - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Measles Vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Measles and Rubella Vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Measles Vaccine - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 measles rubella vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Vaccine for Measles - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecule to Inhibit RNA-Dependent RNA Polymerase for Measles - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Vaxfectin-Formulated Measles DNA Vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 MMR + Varicella Vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ERDRP-0519 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Vaccine for Measles and Rubella - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Measles - Recent Pipeline Updates 48 Measles - Dormant Projects 50 Measles - Product Development Milestones 51 Featured News & Press Releases 51 Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 51 Aug 21, 2008: Vaxfectin Formulated Measles DNA Vaccine Could Address Unmet Need for Infants 51 Sep 06, 2005: FDA Approves ProQuad, the First and Only Vaccine in the U.S. to Help Protect Children Against Measles, Mumps, Rubella and Chickenpox in One Shot. ProQuad Combines Two Well-Established Merck Vaccines, M-M-R II and VARIVAX. 52 Nov 04, 2004: Merck Files Biologics License Application for ProQuad With U.S. Food and Drug Administration. 52 May 13, 2004: ProQuad, Merck's Investigational Combination Vaccine, Resulted in Antibody Responses Similar to Those with M-M-R IIand Varivax in New Study. 52 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 55 Disclaimer 55
List of Tables Number of Products under Development for Measles, H2 2014 8 Number of Products under Development for Measles - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Measles - Pipeline by Vical Incorporated, H2 2014 18 Measles - Pipeline by GlaxoSmithKline plc, H2 2014 19 Measles - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 20 Measles - Pipeline by Cadila Pharmaceuticals Ltd., H2 2014 21 Measles - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2014 22 Measles - Pipeline by Serum Institute of India Limited, H2 2014 23 Measles - Pipeline by Universal Stabilization Technologies, Inc., H2 2014 24 Assessment by Monotherapy Products, H2 2014 25 Assessment by Combination Products, H2 2014 26 Number of Products by Stage and Target, H2 2014 28 Number of Products by Stage and Mechanism of Action, H2 2014 30 Number of Products by Stage and Route of Administration, H2 2014 32 Number of Products by Stage and Molecule Type, H2 2014 34 Measles Therapeutics - Recent Pipeline Updates, H2 2014 48 Measles - Dormant Projects, H2 2014 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.